LongCovid
Why do some people infected with COVID-19 develop postacute sequelae of COVID-19 (PASC) while others do not?
This is the question that Herman et al. try to answer with this recently published study. The article shows that the presence of functional antibodies specific to OC43 (endemic human coronavirus) was enriched in PASC, suggesting immunological imprinting specific to OC43 may be a driver of PASC, particularly in individuals with prior rheumatic disease.
An excelent systematic review of trials currently investigating treatment for Post-Acute COVID Syndrome (PACS)/longCOVID has been published by the Clinical Microbiology and Infection (CMI). The review identified 388 registered trials exploring 144 unique interventions…
The H2020 PERISCOPE project investigates the broad socio-economic and behavioural impacts of the COVID-19 pandemic, to make Europe more resilient and prepared for future large-scale risks. Recently, the…
Currently, there are no curative therapies for Post-COVID or ME/CFS. A German study led by Charité – Universitätsmedizin Berlin proposes the evaluation of drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic…
Do not miss the chance to learn more about the project’s updates for the past months. You can subscribe now on the contact section of this website.